Sarah Cannon Research Institute’s Post

⚡ Nivolumab plus platinum-doubletchemotherapy in treatment-naive patientswith advanced grade 3 NeuroendocrineNeoplasms of gastroenteropancreatic orunknown origin: The multicenter phase 2NICE-NEC trial (GETNE-T1913) 🦓 #NeuroendocrineTumors https://buff.ly/46MiN8T

Dr. Anup Kasi will be presenting an interim update of the on-going clinical trial results of misetionamide (GP-2250) at the Visceral Medicine Conference in Leipzig, Germany on October 4th at 1:45 p.m. CEST.   This presentation will provide an update on Panavance’s Phase 1 trial exploring the safety, tolerability and early potential of misetionamide (GP-2250) in advanced pancreatic adenocarcinoma.   For more details: https://lnkd.in/e3CBgtRr   #visceralmedicineconference #pancreaticcancer #pancreaticadenocarcinoma #clinicaltrialresults

Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept Today, Opthea announced that it has completed enrollment of all patients in the COAST Phase 3 pivotal clinical trial investigating sozinibercept (OPT-302, a vascular endothelial growth factor (VEGF)-C/D inhibitor) in combination with aflibercept, an anti-VEGF-A therapy, for the treatment of wet Age-related Macular Degeneration (wet AMD). The sozinibercept clinical program includes two Phase 3 pivotal trials, COAST and ShORe. Enrollment in ShORe is expected to be completed in calendar Q2 2024. Opthea intends to report topline results from these two trials by mid-2025. #maculardegeneration #ophthalmology #retinalspecialists #progress #wetAMD #WetAMDClinicalTrials #wetAMDstudies #clinicaltrials Frederic Guerard Ian Leitch Peter Lang Judy J. Robertson Fang Li, PhD RAC Julie Clark Bruno Gagnon Sarah Weeks Ashima Brar, MD, MBA Silvana Guerci-Lena Learn More: https://lnkd.in/e8wcMCdi

💡 Join Dr. Vince Clinical Research for an upcoming webinar on managing renal and hepatic impairment trials. These trials are essential for assessing the impact of organ impairment on #pharmacokinetics (PK), but recruitment challenges make them more complex than standard clinical studies. Learn how tools like population PK (PopPK) and physiologically based PK (#PBPK) modeling, combined with adaptive trial designs, can reduce patient burden and improve trial outcomes. ➡️ Learn more + register here: https://buff.ly/4gASg2T #ADME #DrugDevelopment #ClinicalResearch #CRO #PatientRecruitment #NASH #NAFLD #TherapeuticAreas #TranslationalResearch #NonalcoholicSteatohepatitis

❓ Which treatment provides better outcomes for #pancreaticcancer after FOLFIRINOX? Read about the CROSSFIRE study, which compared the safety and efficacy of MRI-guided SABR with CT-guided percutaneous irreversible electroporation following FOLFIRINOX:

Human Clinical Article: This phase IIA clinical trial reports the safety and therapeutic efficacy of autologous chondroprogenitor cells derived from the nasal septum for the treatment of patients with temporomandibular joint. https://lnkd.in/d6mUJAxq

🚨 Exciting Webinar Announcement! 🚨 Join us for the Joint Avicenna Webinar today, September 10th, 2024 at 5 PM CEST, featuring Revital Rattenbach from 4P-Pharma and Amichai Perlman from QuantHealth. They will present groundbreaking insights on "Integrating In Silico and In Vivo Data to Optimize Plerixafor Treatment for ARDS." 🔬 ARDS (Acute Respiratory Distress Syndrome) is a life-threatening condition with limited treatment options. This research explores the synergy between in silico simulations and in vivo preclinical data to identify optimal patient responders for Plerixafor treatment. Key highlights include: 👉 Plerixafor shows potential in reducing NETosis, especially in intubated patients and across various ARDS etiologies. 👉 A novel approach focuses on targeting subpopulations based on severity rather than etiology. 👉 The integration of data sources is pivotal for developing personalized ARDS therapies. REGISTRATION: https://lnkd.in/ds3wRzmf Don't miss this opportunity to explore how data-driven approaches are shaping the future of personalized medicine for ARDS! #Webinar #Pharma #HealthcareInnovation #ARDS #InSilico #InVivo #PersonalizedMedicine #Research

Our CSO Martin Gosling was recently interviewed by Labiotech for an article discussing how new treatments for #cysticfibrosis (CF) are boosting life expectancy. Just three decades ago, the average life expectancy of people with CF was around 30 years of age. This has now improved to 50, with some patients living into their 80s. Recent advancements in CF research have played a key role in contributing to this. One section of the article discusses how Enterprise Therapeutic’s EDT001 has the potential to meet the needs of people with CF. In preclinical studies, ETD001 boosted the clearance of mucus for longer than 12 hours after a single dose, and Phase 1 studies showed a pharmacokinetic profile consistent with long lung retention. Phase 2 trials are due to begin this month. ETD001 has the potential to treat people with cystic fibrosis not currently eligible or receiving benefit from CFTR modulators, and further improve lung function when administered in combination with CFTR modulators. Read more about new treatments for people with #CF here: https://rb.gy/1jdi5x

We are excited to share data from the first cohort of the LIGHTHOUSE study, our ongoing Phase I/II clinical trial evaluating our investigational #GeneTherapy ATSN-201 for the treatment of X-linked retinoschisis (#XLRS). For the first time in patients, we have validated the ability of AAV.SPR, our novel spreading #capsid, to spread laterally well beyond the subretinal injection blebs. Additionally, we have demonstrated the ability to safely administer subretinal injections in patients with extensive retinal schisis. Subretinal injection of ATSN-201 was well tolerated in all three patients in the first cohort with two patients showing extensive resolution of schisis beginning at 8 weeks after dosing. Additional and continued resolution of schisis was observed through week 24, the latest time point available. Read more about the data in our press release: https://lnkd.in/eAcpdUHS

#EASL2024 has come to an end. There were significant milestones, including the announcement of clinical results demonstrating excellent clinical efficacy and the listing of the first drug approved for MASH use in clinical guidelines. Above all, it was impressive that the room became solemn as many presenters paid tribute to Dr. Harrison... R.I.P. We would also like to thank the many people who came to see the poster presentation of #DA1241, a first-in-class potential #GPR119 agonist. Please find the poster files if you are interested: [THU-531] Synergistic effect in combo with #Semaglutide in liver #fibrosis mice: https://lnkd.in/g3DFU--M [THU-232] Drastic enhanced anti-MASH effect when combined with #Semaglutide in GAN diet-induced #MASH mice: https://lnkd.in/gcCbzAP7